Physician profile
Mark A Gallardo
NPI 1336159607
$15,196.00
in general payments reported to CMS, 2019-2025
40 companies · $1,581 in 2025
The $1,581 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,138 · 2020: $989 · 2021: $1,531 · 2022: $1,739 · 2023: $1,895 · 2024: $1,322 · 2025: $1,581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,632 · Education: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,631.62 |
| Education | $166.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $5,000.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $2,278.12 | 2019-2025 | |
| Abbvie INC. | $1,362.48 | 2019-2025 | |
| Genzyme Corporation | $707.86 | 2019-2025 | |
| Janssen Biotech, INC. | $571.67 | 2019-2025 | Tremfya |
| Incyte Corporation | $555.86 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $486.89 | 2020-2025 | Adbry, Anzupgo |
| Amgen INC. | $411.99 | 2019-2025 | Otezla, Otezla |
| Epi Health, LLC | $391.76 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $380.34 | 2019-2024 | Arazlo, Cabtreo, Duobrii |
| Arcutis Biotherapeutics, INC. | $357.73 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $344.94 | 2020-2025 | Nemluvio, Aklief, Oracea |
| Regeneron Healthcare Solutions, INC. | $301.80 | 2020-2025 | Dupixent |
| Pfizer INC. | $214.66 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $207.82 | 2019-2025 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $207.19 | 2023-2024 | Sotyktu |
| Prugen, INC. Pharmaceuticals | $159.64 | 2020 | |
| Lilly USA, LLC | $155.69 | 2019-2025 | Ebglyss, Taltz, Olumiant |
| Biofrontera INC. | $146.62 | 2019-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Ucb, INC. | $140.86 | 2019-2025 | Bimzelx |
| Janssen Scientific Affairs, LLC | $98.35 | 2019 | |
| Dermavant Sciences, INC. | $84.19 | 2022-2024 | Vtama |
| Almirall LLC | $69.71 | 2021-2025 | Seysara, Klisyri |
| Hill Dermaceuticals, INC. | $65.40 | 2023-2024 | Tolak |
| Organon LLC | $61.79 | 2025 | Vtama |
| Strata Skin Sciences, INC. | $55.11 | 2020-2024 | Xtrac |
| Vyne Pharmaceuticals INC. | $48.62 | 2021 | |
| Medimetriks Pharmaceuticals, INC. | $46.95 | 2025 | Neo-Synalar |
| Dusa Pharmaceuticals, INC. | $44.87 | 2019 | |
| Genentech USA, INC. | $39.38 | 2019 | |
| Organogenesis INC. | $27.59 | 2023 | Puraply |
| Novo Nordisk INC | $26.40 | 2022 | |
| Mallinckrodt Hospital Products INC. | $25.88 | 2025 | Acthar |
| Verrica Pharmaceuticals INC. | $22.11 | 2023 | Ycanth |
| Merck Sharp & Dohme LLC | $20.07 | 2022 | |
| Journey Medical Corporation | $18.55 | 2022 | |
| Botanix Sb INC | $17.14 | 2025 | Sofdra |
| Mission Pharmacal Company | $15.63 | 2021 | |
| Mayne Pharma Commercial LLC | $13.08 | 2024 | |
| Celgene Corporation | $11.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Gallardo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.